Healthcare Jan 18, 2023 10:59 AM (GMT+8) · EqualOcean
BlissBio (Chinese: 百力司康) announced that it had completed a CNY 100 million Series B+ financing round, which was led by In Capital (Chinese: 约印医疗基金) and followed by its existing investors Oriental Fortune Capital (Chinese: 东方富海) and Sherpa Healthcare Partners (Chinese: 夏尔巴资本). Proceeds raised in this round will be used in the advancement of clinical research of BB-1701, BB-1705, BB-1709 programs, pre-clinical research and registration of product pipelines, and the preparation of new drug application. BB-1701 is a new antibody-drug conjugate (ADC) under Phase II clinical trial. Its toxin Eribulin, licensed from Eisai, is an oncology product on the market with clinically proven safety and efficacy profiles.